OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76

Showing 26-50 of 76 citing articles:

Multi-omics dissection of Parkinson’s patients in subgroups associated with motor and cognitive severity
Efi Athieniti, Sotiroula Afxenti, George Minadakis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access

GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins
Yuxin Fang, Yaojin Zhu, Wei Wang, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access

Recent advances in targeted degradation in the RAS pathway
Zhiming Ge, Zisheng Fan, Wei He, et al.
Future Medicinal Chemistry (2025), pp. 1-16
Closed Access

Drosophila as a Promising In Vivo Research Model for the Application and Development of Targeted Protein Inactivation Technologies
Н. В. Дорогова, С. А. Федорова
Archives of Insect Biochemistry and Physiology (2025) Vol. 118, Iss. 3
Closed Access

Extracellular vesicles in cancer´s communication: messages we can read and how to answer
Alena Semerádtová, Michaela Liegertová, Regina Herma, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access

Multivalent DNA lysosome-targeting chimaera for targeted protein degradation and inhibition of c-Met signaling pathways
Xinhuan Chen, Mengmeng Ji, Xue Bai, et al.
Chemical Engineering Journal (2025), pp. 161974-161974
Closed Access

PROTACS: A technology with a gold rush-like atmosphere
Yuwei Wang, Li Lan, Min Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115037-115037
Closed Access | Times Cited: 21

Bioorthogonally Activatable Autophagy-Tethering Compounds for Aptamer-Guided Mitochondrial Degradation
Mengmeng Liu, Zhenqi Liu, Geng Qin, et al.
Nano Letters (2023) Vol. 23, Iss. 11, pp. 4965-4973
Closed Access | Times Cited: 12

The role of redox-mediated lysosomal dysfunction and therapeutic strategies
Xiaomeng He, Xuening Li, Wei Tian, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115121-115121
Open Access | Times Cited: 12

Emerging drug design strategies in anti-influenza drug discovery
Chuanfeng Liu, Lide Hu, Guanyu Dong, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 12, pp. 4715-4732
Open Access | Times Cited: 12

The application of PROTAC in HDAC
Shaoting Chen, Yuxiang Zheng, Benji Liang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115746-115746
Closed Access | Times Cited: 12

Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC)
Jingying Bao, Zhenqian Chen, Yu Li, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 15, Iss. 1, pp. 29-35
Closed Access | Times Cited: 12

Bioorthogonal Aptamer‐ATTEC Conjugates for Degradation of Alpha‐Synuclein via Autophagy‐Lysosomal Pathway
Xiaofeng Liao, Geng Qin, Zhenqi Liu, et al.
Small (2023) Vol. 20, Iss. 8
Open Access | Times Cited: 11

Autophagy mediated targeting degradation, a promising strategy in drug development
Jiantao Zhang, Xiangyi Pan, Wenshu Ji, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107466-107466
Closed Access | Times Cited: 4

Discovery of 2,4-Quinazolinedione Derivatives as LC3B Recruiters in the Facilitation of Protein Complex Degradations
Yanping Zeng, Jian Xiao, Shi Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117293-117293
Closed Access

Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access

Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases
Yuqi Fu, Jin Zhang, Rui Qin, et al.
Pharmacological Reviews (2025), pp. 100053-100053
Closed Access

Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains
Chuhui Huang, Claire L. Harris, Ghizal Siddiqui, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 4, pp. 978-1012
Closed Access

Strategies for Precise Modulation of Protein Degradation
Shipeng He, Guoqiang Dong, Chunquan Sheng
Accounts of Chemical Research (2025)
Closed Access

Covalent inhibitors possessing autophagy-modulating capabilities: charting novel avenues in drug design and discovery
Yutong Wang, Shiyu Luo, Hongbao Sun, et al.
Drug Discovery Today (2025), pp. 104347-104347
Closed Access

Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
Jiachan Lin, Zirui Chen, Dan Zhang, et al.
Macromolecular Rapid Communications (2025)
Closed Access

Palmitoylation in cardiovascular diseases: Molecular mechanism and therapeutic potential
Rongli Wang, Yi He, Yan Wang, et al.
IJC Heart & Vasculature (2025) Vol. 58, pp. 101675-101675
Closed Access

Targeting the autophagy-lysosomal pathway in Huntington disease: a pharmacological perspective
Junsheng Yang, Chaoyue Zhang
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 10

TAC‐tics for Leveraging Proximity Biology in Drug Discovery
Dhanusha A. Nalawansha, Kyle Mangano, Willem den Besten, et al.
ChemBioChem (2023) Vol. 25, Iss. 4
Closed Access | Times Cited: 9

Scroll to top